PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE vork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/554,732-Conf. #9693 **INFORMATION DISCLOSURE** Filing Date January 5, 2007 STATEMENT BY APPLICANT First Named Inventor Christian Hubschwerlen Art Unit 4161 (Use as many sheets as necessary) Examiner Name P. E. Zarek 2 64391(41925) Sheet 1 Attorney Docket Number

		U.S. PA	TENT DOCUMENTS	
Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
No.		IVIIVI-DID-1711	Applicant of Cited Document	Figures Appear
AA*	US-2004/0132764	07-08-2004	Locher	
AB*	US-2007/0004769	01-04-2007	Hubschwerlen et al.	
<u> </u>				
	No. <sup>1</sup>	Cite No.1 Number-Kind Code <sup>2</sup> ( <i>if known</i> )  AA* US-2004/0132764	Cite No.1         Document Number Number         Publication Date MM-DD-YYYY           AA*         US-2004/0132764         07-08-2004	No.1 Number-Kind Code <sup>2 (if known)</sup> MM-DD-YYYY Applicant of Cited Document  AA* US-2004/0132764 07-08-2004 Locher

		FOREI	GN PATENT	DOCUMENTS	·	
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (# known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	
	ВА	WO-03/031441-A1	04-17-2003	Morphochem AG Aktiengesellschaft Für Kombinatorische Chemie		
	ВВ	WO-03/031443-A1	04-17-2003	Morphochem AG Aktiengesellschaft Für Kombinatorische Chemie		
	вс	WO-03/032962-A2	04-24-2003	Morphochem AG Aktiengesellschaft Für Kombinatorische Chemie		
	BD	WO-2005/058888-A2	06-30-2005	Morphochem AG		
	BE	WO-2005/023801-A1	03-17-2005	Morphochem AG		
	BF	KR-10 2000 00673606	11-15-2000	Korea Institute of Science and Technology		~
	BG	WO 01/46164	06-28-2001	Ortho-McNeil Pharmaceutical, Inc.		

Examiner	Date	
Signature	 Considered	
		1

OCT 2 0 2009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Su	bstitute for form 1449/PTO			Complete if Known		
				Application Number	10/554,732-Conf. #9693	
il	NFORMATIO	N DIS	CLOSURE	Filing Date	January 5, 2007	
S	STATEMENT BY APPLICANT			First Named Inventor	Christian Hubschwerlen	
				Art Unit	4161	
	(Use as many sheets as necessary)			Examiner Name	P. E. Zarek	
Sheet	2	of	2	Attorney Docket Number	64391(41925)	

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	C. Hubschwerlen et al., "Design, Synthesis and Biological Evaluation of Oxazolidinone - Quinolone Hybrids", <i>Bioorganic &amp; Medicinal Chemistry</i> , Vol. 11, pgs. 2313-2319 (2003).	
	СВ	C. Hubschwerlen et al., "Structure-Activity Relationship in the Oxazolidinone-Quinolone Hybrid Series: Influence of the Central Spacer on the Antibacterial Activity and the Mode of Action", <i>Bioorganic &amp; Medcinal Chemistry</i> , Vol. 13, pgs. 4229-4233 (2003).	
	СС	Locher et al., "Synthesis and Antibacterial Action of Novel Quinolone-linked Oxazolidinones", 42th ICAAC (2002), poster and abstract F-1317, ICAAC 2002: San Diego, CA, September 27-30, 2002.	
	CD	Hubschwerlen et al., "New Qxazolidinone-Quinolone Hybrids: Synthesis and SAR", 43rd ICAAC (2003), abstract F-2144, Chicago, IL, September 14-17, 2003.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)	Complete if Known			
	IFORMATION DISCLOSURI TATEMENT BY APPLICAN		Application Number	10/554,732-Conf. #9693	
11	<b>NFORMATION</b>	l DI	SCLOSURE	Filing Date	January 5, 2007
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Christian Hubschwerlen
	STATEMENT BY APPLICANT			Art Unit	4161
				Examiner Name	P. E. Zarek
Sheet	1	of	2	Attorney Docket Number	64391(41925)

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-2004/0132764	07-08-2004	Locher	
	AB*	US-2007/0004769	01-04-2007	Hubschwerlen et al.	
	ļ				
-			- ···· .		
	<u> </u>			- · · · · · · · · · · · · · · · · · · ·	
	<b> </b>				
ļ	ļ				,
L	L				1.

		FOREI	GN PATENT	DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
	ВА	WO-03/031441-A1	04-17-2003	Morphochem AG Aktiengesellschaft Für Kombinatorische Chemie		
	BB	WO-03/031443-A1	04-17-2003	Morphochem AG Aktiengesellschaft Für Kombinatorische Chemie		
	вс	WO-03/032962-A2	04-24-2003	Morphochem AG Aktiengesellschaft Für Kombinatorische Chemie		
	BD	WO-2005/058888-A2	06-30-2005	Morphochem AG		
	BE	WO-2005/023801-A1	03-17-2005	Morphochem AG		
	BF	KR-10 2000 00673606	11-15-2000	Korea Institute of Science and Technology		1
_	BG	WO 01/46164	06-28-2001	Ortho-McNeil Pharmaceutical, Inc.		

Examiner	Date
Signature	Considered

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Sub	ostitute for form 1449/PTO			Complete if Known		
				Application Number	10/554,732-Conf. #9693	
l in	NFORMATIO	N DIS	SCLOSURE	Filing Date	January 5, 2007	
l s	STATEMENT BY APPLICANT			First Named Inventor	Christian Hubschwerlen	
				Art Unit	4161	
	(Use as many sheets as necessary)			Examiner Name	P. E. Zarek	
Sheet	2	of	2	Attorney Docket Number	64391(41925)	

Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	C. Hubschwerlen et al., "Design, Synthesis and Biological Evaluation of Oxazolidinone - Quinolone Hybrids", <i>Bioorganic &amp; Medicinal Chemistry</i> , Vol. 11, pgs. 2313-2319 (2003).	
	СВ	C. Hubschwerlen et al., "Structure-Activity Relationship in the Oxazolidinone-Quinolone Hybrid Series: Influence of the Central Spacer on the Antibacterial Activity and the Mode of Action", <i>Bioorganic &amp; Medcinal Chemistry</i> , Vol. 13, pgs. 4229-4233 (2003).	
<u>-</u> ,	СС	Locher et al., "Synthesis and Antibacterial Action of Novel Quinolone-linked Oxazolidinones", 42th ICAAC (2002), poster and abstract F-1317, ICAAC 2002: San Diego, CA, September 27-30, 2002.	
	CD	Hubschwerlen et al., "New Qxazolidinone-Quinolone Hybrids: Synthesis and SAR", 43rd ICAAC (2003), abstract F-2144, Chicago, IL, September 14-17, 2003.	

Examiner	Date	i
Signature	Considered	i

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.